

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
6 November 2003 (06.11.2003)

PCT

(10) International Publication Number
WO 03/090740 A1

(51) International Patent Classification⁷: **A61K 31/22,**
31/265, A61P 31/04

(74) Agent: **GROS, Glorent**; Novartis AG, Corporate Intellectual Property, Patent & Trademark Department, CH-4002 Basel (CH).

(21) International Application Number: **PCT/EP03/04173**

(22) International Filing Date: **22 April 2003 (22.04.2003)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SK, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW.

(30) Priority Data:
0209262.5 **23 April 2002 (23.04.2002)** **GB**

(84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR).

(71) Applicant (*for all designated States except US*): **BIO-CHEMIE GESELLSCHAFT M.B.H.** [AT/AT]; 6250 Kundl (AT).

Published:

— *with international search report*

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ASCHER, Gerd** [AT/AT]; Daxerfeld 3, A-6250 Kundl (AT). **HILDEBRANDT, Johannes** [DE/AT]; St. Laurentgasse 12, A-2512 Oeynhausen (AT).

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/090740 A1

(54) Title: **USE OF PLEUROMUTILINS FOR THE TREATMENT OF DISORDERS CAUSED BY HELICOBACTER PYLORI**

(57) Abstract: A method of preventing or treating diseases mediated by *Helicobacter pylori*, comprising administering to a subject in need of such treatment an effective amount of a pleuromutilin.